Ascenta Therapeutics, Inc. – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 1 PAGES: 67

More Info
									 Ascenta Therapeutics, Inc. – Product Pipeline Review
                     – H2 2011
                                                                                          Reference Code: GMDHC01769CDB

                                                                                                 Publication Date: NOV 2011




Ascenta Therapeutics, Inc. – Product Pipeline Review – H2 2011                              GMDHC01769CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Ascenta Therapeutics, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 4
      List of Figures .................................................................................................................................................................................................... 5
Ascenta Therapeutics, Inc. Snapshot ....................................................................................................................................................................... 6
      Ascenta Therapeutics, Inc. Overview ................................................................................................................................................................. 6
      Key Information .................................................................................................................................................................................................. 6
      Key Facts ........................................................................................................................................................................................................... 6
Ascenta Therapeutics, Inc. – Research and Development Overview ........................................................................................................................ 7
      Key Therapeutic Areas ....................................................................................................................................................................................... 7
Ascenta Therapeutics, Inc. – Pipeline Review .........................................................................................................................................................10
      Pipeline Products by Stage of Development ......................................................................................................................................................10
      Pipeline Products – Monotherapy .....................................................................................................................................................................11
      Pipeline Products – Combination Treatment Modalities .....................................................................................................................................12
Ascenta Therapeutics, Inc. – Pipeline Products Glance ...........................................................................................................................................13
      Ascenta Therapeutics, Inc. Clinical Stage Pipeline Products .............................................................................................................................13
            Phase II Products/Combination Treatment Modalities .................................................................................................................................13
            Phase I Products/Combination Treatment Modalities ..................................................................................................................................14
      Ascenta Therapeutics, Inc.–Early Stage Pipeline Products ...............................................................................................................................15
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................15
Ascenta Therapeutics, Inc. – Drug Profiles ..............................................................................................................................................................16
      AT-101 ..............................................................................................................................................................................................................16
            Product Description ....................................................................................................................................................................................16
            Mechanism of Action...................................................................................................................................................................................16
            R&D Progress .............................................................................................................................................................................................16
      AT-101 + Docetaxel + 5-Fluorouracil + Radiation Therapy ................................................................................................................................17
            Product Description ....................................................................................................................................................................................17
            Mechanism of Action...................................................................................................................................................................................17
            R&D Progress .............................................................................................................................................................................................18
      AT-101 + Prednisone + Docetaxel.....................................................................................................................................................................19
            Product Description ....................................................................................................................................................................................19
            Mechanism of Action...................................................................................................................................................................................19
            R&D Progress .............................................................................................................................................................................................19
      AT-101 + Rituxan ..............................................................................................................................................................................................21
            Product Description ....................................................................................................................................................................................21
            Mechanism of Action...................................................................................................................................................................................21
            R&D Progress .............................................................................................................................................................................................21
      AT-101 + Taxotere ............................................................................................................................................................................................22
            Product Description ....................................................................................................................................................................................22
            Mechanism of Action...................................................................................................................................................................................22
            R&D Progress .............................................................................................................................................................................................22
      AT-101 + Temodar + Radiation Therapy ...........................................................................................................................................................23
            Product Description ....................................................................................................................................................................................23
            Mechanism of Action...................................................................................................................................................................................23
            R&D Progress .............................................................................................................................................................................................23
      AT-101 + Topotecan .........................................................................................................................................................................................24
            Product Description ....................................................................................................................................................................................24




Ascenta Therapeutics, Inc. – Product Pipeline Review – H2 2011                                                                                              GMDHC01769CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Ascenta Therapeutics, Inc. – Product Pipeline Review



           Mechanism of Action...................................................................................................................................................................................24
           R&D Progress .............................................................................................................................................................................................24
     AT-406 ..............................................................................................................................................................................................................25
           Product Description ....................................................................................................................................................................................25
           Mechanism of Action...................................................................................................................................................................................25
           R&D Progress .............................................................................................................................................................................................25
     AT-406 + Daunorubicin + Cytarabine ................................................................................................................................................................26
           Product Description ....................................................................................................................................................................................26
           Mechanism of Action...................................................................................................................................................................................26
           R&D Progress .............................................................................................................................................................................................26
Ascenta Therapeutics, Inc. – Pipeline Analysis ........................................................................................................................................................28
     Ascenta Therapeutics, Inc. – Pipeline Products by Therapeutic Class ...............................................................................................................28
     Ascenta Therapeutics, Inc. - Pipeline Products By Target .................................................................................................................................29
     Ascenta Therapeutics, Inc. – Pipeline Products by Route of Administration.......................................................................................................31
     Ascenta Therapeutics, Inc. – Pipeline Products by Molecule Type ....................................................................................................................32
Ascenta Therapeutics, Inc. – Recent Pipeline Updates ...........................................................................................................................................33
Ascenta Therapeutics, Inc. - Dormant Projects ........................................................................................................................................................35
Ascenta Therapeutics, Inc. – Locations And Subsidiaries ........................................................................................................................................36
     Head Office .......................................................................................................................................................................................................36
Recent Developments .............................................................................................................................................................................................37
           Jan 31, 2005: First Patient Entered Onto Ascenta Therapeutics' Phase I Trial Of its Lead Product, AT-101, A Pan-Inhibitor Of The Bcl-2
           Protein Family.............................................................................................................................................................................................37
           Feb 27, 2009: Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refactory Prostate Cancer ........37
           May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting..................................38
           May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting ................................39
           Feb 23, 2007: Ascenta Therapeutics Presents New Clinical Data On AT-101 Monotherapy for the Treatment of Hormone-Refractory
           Prostate Cancer ..........................................................................................................................................................................................39
           Apr 21, 2009: Ascenta Therapeutics Announces Results Of Preclinical Evaluation Of AT-406 In Multiple Cancer Models ..........................39
           Nov 18, 2005: Ascenta AT-101 Clinical Trial Data Presented At The AACR-NCI-EORTC International Conference On Molecular Targets
           And Cancer.................................................................................................................................................................................................40
           Dec 12, 2005: Ascenta AT-101 Data Presented At The American Society Of Hematology 47th Annual Meeting And Exposition In Atlanta,
           Georgia.......................................................................................................................................................................................................40
           Dec 12, 2005: Ascenta AT-101 Data Presented at the American Society of Hematology 47th Annual Meeting and Exposition in Atlanta,
           Georgia.......................................................................................................................................................................................................41
           Dec 10, 2006: Ascenta Therapeutics Presents New Clinical and Biological Data on AT-101 for the Treatment of Chronic Lymphocytic
           Leukemia ....................................................................................................................................................................................................42
           Nov 10, 2005: Phase II Program Of Ascenta's Lead Product, AT-101, A Pan-inhibitor Of The Bcl-2 Protein Family, Begins .......................43
           Oct 09, 2009: Ascenta Therapeutics Receives Clearance To Initiate Clinical Trials With AT-406 ...................
								
To top